Mutations in the E3 ubiquitin ligase RNF216 are known causes of Gordon Holmes syndrome (GHS), a neurodegenerative disorder with neuroendocrine disruption. Using an orthogonal ubiquitin transfer (OUT) platform applied to neuronal cells, the authors profiled RNF216 substrates to define molecular pathways downstream of this ligase. The screen identified the deubiquitinating enzyme OTUD4, which is also mutated in GHS, and the neuronal translational repressor FMRP as prominent RNF216 substrates. The work links RNF216 activity to regulation of protein synthesis and to neuronal structural phenotypes, offering a mechanistic axis that may be relevant to GHS pathogenesis.
The investigators developed and applied an OUT platform in neuronal cells to capture proteins ubiquitinated by RNF216. The source reports that this orthogonal approach enabled direct identification of RNF216 substrates in a cellular context relevant to nervous system biology. Details on experimental parameters, controls, or validation methods beyond the OUT platform description were not reported in the source abstract and would be found in the full manuscript.
Among the substrates detected, OTUD4 and FMRP were highlighted. OTUD4 is a deubiquitinating enzyme previously implicated in GHS, while FMRP is a neuronal-enriched translational repressor. The identification of these proteins positions RNF216 at the intersection of ubiquitin-mediated proteostasis and translational control within neurons.
The authors report that RNF216 predominantly synthesizes K6-linked ubiquitin chains on OTUD4, which leads to OTUD4 degradation. In neurons, ubiquitinated OTUD4 forms donut-shaped structures. Conversely, OTUD4 removes ubiquitin from RNF216 and from FMRP, indicating reciprocal regulation: RNF216 promotes OTUD4 turnover, while OTUD4 counteracts ubiquitination of RNF216 and FMRP. These findings describe a bidirectional regulatory axis between an E3 ligase and a DUB that directly affects the ubiquitination status and stability of each partner and of at least one translational regulator.
Analysis of the RNF216 substrate set revealed enrichment for biological functions involved in protein synthesis, suggesting that RNF216 activity impacts translational pathways broadly. Functionally, the source reports that RNF216 expression increased rates of protein synthesis across different cell types. In neurons, deletion of Rnf216 decreased dendritic development, linking RNF216 activity to neuronal morphology and potentially to synaptic or circuit-level outcomes. The source positions these functional readouts as evidence that RNF216 and OTUD4 together balance rates of protein synthesis and degradation in neuronal cells.
Because mutations in RNF216 cause GHS and OTUD4 is also mutated in GHS, the authors propose that disturbances in the RNF216–OTUD4 regulatory axis may contribute to disease. Specifically, alterations that shift the balance between protein synthesis and degradation—either via loss of RNF216 ligase activity, altered ubiquitination of OTUD4, or impaired deubiquitination—could trigger proteostatic and translational dysregulation that progresses to neurodegeneration. The source frames this mechanistic model as a potential explanation for how mutations in either gene might converge on shared cellular pathways relevant to GHS.
The abstract-focused source summarizes major findings but does not present full experimental details, quantitative metrics, or extended validation data. The OUT platform and substrate identifications are described at a high level; precise methods, sample sizes, and statistical analyses were not included in the source abstract. Further investigation in the full manuscript would be required to assess the robustness of substrate calls, the ubiquitylation linkage specificity across contexts, the mechanistic basis for donut-shaped OTUD4 structures, and how these molecular events translate to in vivo disease phenotypes. Additional studies will be needed to test whether GHS-associated patient mutations in RNF216 or OTUD4 produce the predicted shifts in protein synthesis or neuronal structure in relevant model systems.
This study uses an orthogonal ubiquitin transfer strategy to map RNF216 substrates in neuronal cells and identifies a reciprocal regulatory relationship between RNF216 and OTUD4 that connects ubiquitin signaling to translational control. The coupling of RNF216 activity to protein synthesis rates and neuronal dendritic development provides a plausible cellular mechanism by which mutations in RNF216 or OTUD4 could contribute to Gordon Holmes syndrome. The source reports funding support and declares no competing interests. For methodological specifics, quantitative results, and complete experimental context, readers should consult the full preprint.